News | Contrast Media | July 03, 2023

Preferential use of pulmonary MR angiography (MRA) for diagnosing pulmonary embolus (PE) in the general population helped conserve iodinated contrast media during the 2022 shortage 

Preferential use of pulmonary MR angiography (MRA) for diagnosing pulmonary embolus (PE) in the general population helped conserve iodinated contrast media during the 2022 shortage

Patient was found to have deep vein thrombosis. Gadolinium-enhanced MRA was performed to assess for pulmonary embolus (PE). Coronal contrast-enhanced T1-weighted images in pulmonary arterial phase (A) and low flip-angle delayed phase (B) show PE (arrows, A and B). Delayed-phase image also shows cardiac chamber (star) and ascending thoracic aorta (chevron). Multiphase acquisition of MRA during inflow and outflow of contrast agent from pulmonary arteries is in distinction to single acquisition of CTA and may facilitate obtaining optimal enhancement of pulmonary arteries. Image courtesy of AJR 


July 3, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR), preferential use of pulmonary MR angiography (MRA) for diagnosing pulmonary embolus (PE) in the general population helped conserve iodinated contrast media during the 2022 shortage. 

“This single-center experience demonstrates use of pulmonary MRA as a practical substitute for pulmonary CTA in emergency settings,” concluded lead investigator Jitka Starekova, MD, from the radiology department of the University of Wisconsin in Madison.   

Starekova et al.’s study included all CTA and MRA examinations performed to exclude PE at their large academic medical center (University of Wisconsin-Madison Hospital and Clinics) from April 1 through July 31 (18 weekly periods) in:   

2019 (before the COVID-19 pandemic and contrast media shortage), 

2021 (during the pandemic, though before the shortage), 

2022 (during both the pandemic, as well as the shortage). 

To help preserve iodinated contrast media, from early May through mid-July of 2022, MRA served as the preferred test for PE diagnosis. Upon reviewing CTA and MRA reports, Starekova and her AJR colleagues estimated iodinated contrast media savings via preferential MRA usage. 

Ultimately, preferred use of pulmonary MRA to diagnosis PE among the general population conserved (from April 1 to July 31, 2022) an estimated 27 liters of iohexol (Omnipaque) 350mg/ml. During weeks 8-11, more MRA examinations (range, 45-63) than CTA examinations (range, 27-46) were performed. 

Noting their AJR accepted manuscript evaluated MRA for PE diagnosis in “an all-comer real-world setting,” the present study also includes a larger sample size in comparison to previous research. 

For more information: www.arrs.org


Related Content

News | Magnetic Resonance Imaging (MRI)

March 4, 2026 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Bayer for the expanded ...

Time March 04, 2026
arrow
News | Artificial Intelligence

March 2, 2026 — RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France. Gleamer will be ...

Time March 03, 2026
arrow
News | HIMSS

March 3, 2026 — MedDream will present its cloud-native, AI-ready universal DICOM viewer in the Amazon Web Services (AWS) ...

Time March 03, 2026
arrow
News

Feb. 26, 2026 — GE HealthCare and UCSF Health have announced a 10-year Care Alliance collaboration focused on ...

Time March 02, 2026
arrow
News | Remote Viewing Systems

Feb. 26, 2026 — DeepHealth, Inc., a provider of AI-powered health informatics and a wholly owned subsidiary of RadNet ...

Time February 27, 2026
arrow
News | FDA

Feb. 26, 2026 — The U.S. Food and Drug Administration (FDA) has given 510(k) class II clearance of qXR-Detect, the ...

Time February 26, 2026
arrow
News | Contrast Media

Feb. 23, 2026 — Bracco, a global leader in diagnostic imaging, recently announced that the U.S. Food and Drug ...

Time February 24, 2026
arrow
News | Radiology Imaging

Feb. 12, 2026 — Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care ...

Time February 13, 2026
arrow
News | ARRS

Feb. 11, 2026 —The American Roentgen Ray Society (ARRS) has announced the following radiologists, as well as their ...

Time February 13, 2026
arrow
News | Interventional Radiology

Feb. 2, 2026 — GE HealthCare has announced that Allia Moveo has received U.S. Food and Drug Administration (FDA) 510(k) ...

Time February 02, 2026
arrow
Subscribe Now